Ozempic Face: Causes, Whether It Goes Away and Treatment

Ozempic face is a nickname for the facial change some people notice after losing a lot of weight: hollower cheeks, a gaunt look, new wrinkles and looser skin on the face and neck. Cleveland Clinic adds that losing the fat pads around the eyes can make them look deeper set, and that loose skin on the cheeks and jaw can form jowls. It is not a medical term. Cleveland Clinic traces it to social media, where a celebrity dermatologist used it, and notes it is probably not a phrase your own clinician will use. An ASPS member surgeon calls it a lay term for facial deflation after rapid weight loss, not a medical diagnosis.

The name points at one drug, but the cause does not. Cleveland Clinic describes it as a side effect of the rapid weight loss the medication can bring rather than of the medication itself, and says the same change can follow bariatric surgery or lifestyle changes that cause rapid loss. Surgeons writing for the American Society of Plastic Surgeons (ASPS) make the same point: the underlying changes are not unique to the medication.

The brand names are worth getting right. Ozempic is semaglutide approved by the FDA for adults with type 2 diabetes, to improve blood sugar control and to lower certain heart and kidney risks. Wegovy is the semaglutide product approved, alongside diet and exercise, to reduce excess body weight and keep it off long term. Tirzepatide is sold as Mounjaro and as Zepbound, and Zepbound carries the weight management approval. Everything on this page applies to all of them, and to any large weight loss.

It is also not a health problem in itself. Cleveland Clinic states that it does not bring any negative health effects and does not need treatment unless you want treatment.

This page starts from the weight loss problem: why it happens, whether it reverses, and when and how to treat it. If you want the broader anatomy of restoring the whole face, including age related change in bone and fat across every part of it, read our facial balancing and volume loss guide. The two overlap on treatments. They differ on the question you are asking.

Facial fat shrinks along with body fat, and the skin over it does not always shrink as quickly. ASPS member surgeon Michelle Lee describes the fat pads in the cheeks and temples shrinking too quickly for the skin to retract at the same pace, which leaves a deflated or loose look.

The clearest measurement so far comes from a 2025 study in Otolaryngology Head and Neck Surgery. Researchers at one academic center measured midface volume on CT or MRI scans taken before and after 20 patients, median age 54, started a GLP-1 medication. After an average of 321 days of treatment and 11.0 kg of weight loss, total midface volume fell by a median of 9 percent. The superficial fat just under the skin fell by a median of 11 percent and the deeper fat by 7 percent, and only the superficial loss tracked with how much weight people lost.

The authors summarize it as about 7 percent of midface volume lost for every 10 kg of total weight lost, mostly from the superficial fat pads. It is a small, retrospective study from a single center, so treat that figure as a first estimate rather than a prediction for your own face.

The size of the weight loss on these drugs explains why the change is noticed so often. In the 68 week trial described in the Wegovy label, adults with obesity or overweight lost an average of 14.9 percent of body weight on the 2.4 mg injection, against 2.4 percent on placebo. In the 72 week trial in the Zepbound label, average loss was 15.0 to 20.9 percent across the three doses studied, against 3.1 percent on placebo. Both labels state that the drug lowers body weight with greater loss of fat mass than lean mass, which fits what surgeons describe in the face: it is mostly a change in fat.

Speed, amount and age come up in every primary source we read. Cleveland Clinic states that the faster you lose weight, the more likely you are to experience Ozempic face, and that older adults are more likely to notice it because they have lower fat reserves under the skin even before treatment starts.

Skin quality is the other half. Dr. Lee explains that younger patients typically have more skin elasticity, so their skin is more likely to retract, while fast loss in older patients or those with reduced collagen production makes sagging and hollowing more likely. She adds that when weight comes off gradually and the skin has a chance to retract along with the volume loss, surgeons do not typically see it. The imaging study points the same way: the more weight a person lost, the more superficial midface fat they lost.

None of the sources we found offers a reliable way to predict how a particular face will respond. The practical approach is to notice it early and raise it with the clinician managing your medication, before deciding on any treatment.

Not on its own while the weight stays off. Cleveland Clinic puts it plainly: Ozempic face will not fade with time. If you regain the weight you lost, your face may start looking fuller again, and if you maintain the loss, the effects on your face will likely stay too.

Stopping the medication does not reverse the change by itself; what changes the face is weight coming back. The Zepbound label shows how that tends to play out. In its withdrawal trial, adults lost an average of 20.9 percent of body weight over 36 weeks on the drug. Those then switched to placebo saw their weight rise 14.0 percent between week 36 and week 88, while those who stayed on the drug lost a further 5.5 percent.

So regain can bring some fullness back, but it is not a cosmetic plan. Whether to continue, reduce or stop a GLP-1 medication is a medical decision for you and your prescriber. If you are being treated through a clinic, our overview of how supervised medical weight loss programs work covers what that care should include.

Weight swings also matter for anything done to the face in the meantime. The president of the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) notes that large changes in weight, whether gain or loss, can shorten how long surgical results last, particularly for procedures that rely on soft tissue volume. An ASPS surgeon makes the same point about fat grafting: grafted fat that survives still behaves like fat, enlarging if you gain weight and shrinking if you lose it.

Very little has been proven. We found no controlled trial showing that any diet, exercise plan, supplement or skin treatment prevents facial volume loss during GLP-1 treatment. What exists is sensible guidance for weight loss in general, plus one very small study of a preventive injectable.

Pace. Cleveland Clinic and Dr. Lee both suggest slower loss, about one to two pounds per week. On a GLP-1 medication the pace is shaped largely by the dose schedule your prescriber sets, so this is a conversation to have with them, not a dose change to make yourself.

Protein and strength training. A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society recommends pairing GLP-1 treatment with a structured exercise program that includes regular strength training, along with attention to protein, to preserve muscle and bone. It cites the STEP 1 trial, in which 38 percent of the average weight lost was lean body mass. The advisory is about muscle, bone and overall health, not the face, and no study we found shows these measures prevent facial change. They are still worth doing for their own sake.

Skin basics. Cleveland Clinic also recommends daily sunscreen, a consistent skin care routine, enough protein and staying hydrated. These support skin health in general. They do not replace lost fat.

Collagen supplements. A 2025 meta-analysis of 23 randomized trials with 1,474 participants, published in The American Journal of Medicine, found apparent benefits for skin hydration, elasticity and wrinkles only when industry funded trials were included; trials without industry funding, and the higher quality trials, showed no significant effect. The authors concluded there is currently no clinical evidence to support collagen supplements to prevent or treat skin aging.

Treating early with a collagen stimulator. A 2025 case series in Aesthetic Surgery Journal Open Forum followed 4 women aged 45 to 54 who received two sessions of hyperdilute calcium hydroxylapatite (Radiesse) in the lower face while losing weight on GLP-1 medications. They lost an average of 24.3 pounds, and their average measured cheek volume was 9.8 percent higher at 6 months than before treatment, a change the authors could not show was statistically significant. They call the evidence preliminary: four patients, a retrospective design, self reported weights and no control group. The lead author disclosed a product grant from the manufacturer, and a co-author is employed by Merz Aesthetics. Hyperdilute use in the face is also off label, since the only diluted use in Radiesse labeling is for chest (décolleté) wrinkles, and the Radiesse (+) Lidocaine label includes no diluted use at all. The same physician is running a randomized trial of an estimated 48 participants that is still recruiting, with no results posted.

For surgery, the guidance is specific: wait until your weight is stable. AAFPRS president Patrick Byrne advises that anyone planning to lose more than 10 to 15 pounds wait until their weight is stable before facial plastic surgery, and recommends at least three to six months of stable weight before a facelift, neck lift or eyelid surgery, to avoid excess laxity developing afterward.

He also urges caution with facial fat grafting while someone is still actively losing weight, because facial fat distribution is still changing, and notes that minimally invasive skin tightening may not give lasting results if significant weight loss continues. ASPS surgeons writing about fat grafting after GLP-1 weight loss say patients should ideally be at or near a stable weight, with a long-term plan for their GLP-1 use. One of them prefers to wait until weight has stabilized or is close to target, because treating too early raises the risk of undercorrection, overcorrection or extra procedures as the face keeps changing.

For fillers and collagen stimulators, we found no society guideline that sets a waiting period. The same reasoning applies, though: product placed during rapid loss goes into a face that is still changing, which makes the right amount harder to judge. The case series in section 5 took the opposite approach and treated early. Until the randomized trial reports, that is one group's practice, not an established standard.

Two practical points. Tell every clinician which GLP-1 medication you take and whether you plan to continue, taper or stop, because the plan depends on it. If surgery with sedation or general anesthesia is on the table, the Wegovy label notes rare reports of pulmonary aspiration in people on GLP-1 medications undergoing elective procedures and instructs patients to tell their providers about any planned surgery. Your surgeon and anesthesiologist decide how the medication is handled around it.

The options fall into three groups: injectables that add volume or stimulate collagen, energy devices that work on the skin, and surgery that adds your own fat or lifts and removes loose skin. ASPS surgeon Dr. Lee frames the choice around whether the main issue is focal volume loss, diffuse deflation, or skin and soft tissue laxity. That is the first thing to settle with any provider.

FDA approval is product specific, and the FDA's filler approvals are for adults 22 and older. Juvederm Voluma XC, a hyaluronic acid (HA) filler, is approved for cheek augmentation to correct age related midface volume loss, chin augmentation and, since March 2024, moderate to severe temple hollowing. Sculptra (poly-L-lactic acid) is approved for nasolabial fold contour deficiencies and other facial wrinkles, fine lines and wrinkles in the cheek region, and facial fat loss in people with HIV. Radiesse (calcium hydroxylapatite) is approved for moderate to severe facial wrinkles and folds such as nasolabial folds, facial fat loss in people with HIV, volume loss in the back of the hands and, diluted, chest wrinkles. Radiesse (+) Lidocaine is the same calcium hydroxylapatite gel with a small amount of lidocaine, a numbing agent, added; its U.S. label lists moderate to severe facial wrinkles and folds such as nasolabial folds and, by deep injection, moderate to severe loss of jawline contour in adults over 21, but not the hands, the chest or HIV related fat loss. No label we read names weight loss facial change as an indication, so ask your injector whether the use planned for you is on label.

Reversibility is the other dividing line. The FDA notes that removing filler can require injections, surgery or other interventions, and may be difficult or impossible for fillers that are not made of hyaluronic acid. HA filler can be broken down with an enzyme, hyaluronidase, which injectors also rely on to manage complications; our guide to med spa emergency protocols and hyaluronidase explains what a clinic should keep on hand. For a closer look at how a gel filler and a collagen stimulator differ, see Sculptra vs dermal filler.

Fillers, collagen stimulators and radiofrequency microneedling are office procedures, the kind a medical spa with qualified injectors and medical oversight can provide. None is casual: the FDA says filler injection should be considered a medical procedure, not a cosmetic treatment, and says the same of RF microneedling. Fat grafting, facelift, neck lift and eyelid surgery are operations performed by surgeons.

The evidence for any of these in weight loss facial change specifically is thin. The FDA approved each filler on controlled clinical studies in the face or hands, not in people who lost weight on a GLP-1 medication. The only GLP-1 specific treatment data we found is the four patient case series, and the one randomized trial we found has not reported. We found no GLP-1 specific studies of energy devices, and the FDA's October 2025 safety communication lists fat loss among the serious complications reported with RF microneedling, which deserves weight if lost fat is already your problem.

Surgeons describe a ladder rather than a ranking. ASPS surgeon Michael Dobryansky calls fillers a good starting point, quick, relatively low commitment and reversible, with fat grafting or biostimulatory injectables as the next step for something longer lasting. Dr. Lee finds that global volume loss after substantial GLP-1 weight loss often responds more naturally to fat grafting, and commonly combines volume restoration with a facelift and neck lift when there is significant tissue descent or laxity. These are individual surgeons' views. No source we found names a single preferred treatment.

Price depends on how much product your face needs, so we do not quote a package figure for Ozempic face. For scale on the surgical side, the American Society of Plastic Surgeons puts the average facelift fee at $11,395 and notes that it excludes anesthesia, operating room facilities and other related expenses. Our area guides explain how each treatment is priced and how long it tends to last: cheek filler cost and duration, temple filler cost and duration, nasolabial fold filler cost and duration and Morpheus8 cost per session and per series.

A good consultation for weight loss facial change starts with your weight, not a product. Take these questions with you, and see our fuller list of questions to ask at a med spa consultation.

How does my GLP-1 medication, and the weight I still expect to lose, change what you recommend? Would you treat now or wait for a stable weight, and why? Is my main problem volume, loose skin or both? Which product would you use, what is it FDA approved for, and is this use on label? Can it be dissolved if I dislike the result or if a complication occurs? How many sessions, syringes or vials does the whole plan take? What would happen to the result if I regain weight? Who performs the injection, and what license do they hold?

Red flags: a promise to fix Ozempic face in a single appointment; a large amount of filler recommended while you are still losing weight quickly, with no discussion of timing; no mention of the risk of injection into a blood vessel; an injector who cannot name the product or show you its patient labeling, which the FDA advises you to read and discuss; product bought online, which the FDA warns could be counterfeit or not approved for use in the U.S.; RF microneedling offered without discussing the fat loss the FDA has flagged; and pressure to prepay a long series. Our guide to med spa red flags covers the wider list.

After any filler, the FDA advises seeking immediate medical attention for unusual pain, vision changes, a white, gray or blue appearance of the skin near the injection site, or any sign of a stroke during or shortly after the procedure.